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The goal of this study was to compare brain structure between individuals with generalized anxiety disorder (GAD) and healthy
controls. Previous studies have generated inconsistent findings, possibly due to small sample sizes, or clinical/analytic
heterogeneity. To address these concerns, we combined data from 28 research sites worldwide through the ENIGMA-Anxiety
Working Group, using a single, pre-registered mega-analysis. Structural magnetic resonance imaging data from children and adults
(5–90 years) were processed using FreeSurfer. The main analysis included the regional and vertex-wise cortical thickness, cortical
surface area, and subcortical volume as dependent variables, and GAD, age, age-squared, sex, and their interactions as independent
variables. Nuisance variables included IQ, years of education, medication use, comorbidities, and global brain measures. The main
analysis (1020 individuals with GAD and 2999 healthy controls) included random slopes per site and random intercepts per scanner.
A secondary analysis (1112 individuals with GAD and 3282 healthy controls) included fixed slopes and random intercepts per
scanner with the same variables. The main analysis showed no effect of GAD on brain structure, nor interactions involving GAD,
age, or sex. The secondary analysis showed increased volume in the right ventral diencephalon in male individuals with GAD
compared to male healthy controls, whereas female individuals with GAD did not differ from female healthy controls. This mega-
analysis combining worldwide data showed that differences in brain structure related to GAD are small, possibly reflecting
heterogeneity or those structural alterations are not a major component of its pathophysiology.
Translational Psychiatry          (2021) 11:502 ; https://doi.org/10.1038/s41398-021-01622-1
INTRODUCTION
Research on brain structure in generalized anxiety disorder (GAD)
has generated inconsistent findings, possibly due to small sample
sizes as well as clinical and analytic heterogeneity. The Enhancing
NeuroImaging Genetics through Meta-Analysis (ENIGMA) colla-
boration addresses these challenges in a range of disorders by
pooling neuroimaging data across research sites worldwide [1–5].
Here, we employed the ENIGMA approach to investigate
differences between individuals with GAD and healthy controls
in indices of brain structure in a report from the ENIGMA-Anxiety
Working Group [6]. We conducted a structural magnetic
resonance imaging (MRI) mega-analysis1 using data from 28
Received: 27 August 2021 Revised: 2 September 2021 Accepted: 14 September 2021
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research sites worldwide. The current study compared regional
and vertex-wise cortical thickness, cortical surface area, and
subcortical volume in individuals with GAD and healthy controls,
using methods that accommodate data heterogeneity across the
research sites.
GAD is a highly prevalent and impairing anxiety disorder
notable for its relationship to multiple forms of psychopathology
[7, 8]. Where most anxiety disorders develop in late childhood, the
median age of onset of GAD is in adulthood [9]. Like other
diagnoses, GAD is characterized by clinical heterogeneity, as
individuals with GAD could display many different symptoms
profiles. Moreover, most individuals with GAD suffer from at least
one other mental disorder, particularly other anxiety disorders,
major depressive disorder (MDD), and substance use [7, 8, 10].
Longitudinal and family studies show that genetic risks of GAD
overlap in part with those of MDD and other anxiety disorders
[11–14]. Most prior structural MRI studies rely on voxel-based
morphometry (VBM) and reported altered gray matter volume in a
wide variety of brain regions in individuals with GAD compared to
healthy controls [15–17]. Some, but not others, showed increased
gray matter volume in the amygdala and prefrontal cortex (PFC) as
well as decreased gray matter volume in the hippocampus
[15–17]. Findings on cortical thickness and the surface area
appeared similarly inconsistent [17–20]. One potential explanation
for this inconsistency is clinical heterogeneity.
Small sample sizes and analytical heterogeneity across indivi-
dual studies may also generate inconsistent findings. The ENIGMA
collaboration provides a solution to these problems, by facilitating
the pooling of neuroimaging data across multiple research sites
[5, 21]. This is typically done using meta-analyses, where each
participating research site first processes and analyzes their local
data through a previously agreed common pipeline [1–3]. While
this approach addresses concerns with small sample sizes and
analytic heterogeneity, it uses pooled data for each site. This
prevents the modeling of covariates (such as comorbid disorders)
at the individual subject level. The current study addressed the
latter problem through a mega-analysis, which can be more
powerful than meta-analyses [22], and which allows modeling of
covariates at the subject rather than site-averaged level. The
mega-analytic approach is used less frequently, as working with
individual participant data creates methodological challenges
(e.g., study planning and implementation, international transfer of
data, quality control of large amounts of data) and requires more
computational resources than site-averaged data [23].
The current study assembled raw structural MRI data from 28
research sites, and conducted a pre-registered data analysis [24].
We compared regional and vertex-wise cortical thickness, cortical
surface area, and subcortical volume between individuals with
GAD and healthy controls while examining interactions with age
and sex. Based on prior studies [15–17], we hypothesized that
individuals with GAD would show differences in subcortical
volume in the amygdala and hippocampus and in cortical
thickness and surface area in the PFC compared to healthy
controls. We also expected the association between GAD and
structural measures to differ as a function of participant age, but
we had no specific hypotheses on the direction of this interaction
as previous studies examined the effect of GAD within and not
across age groups [19, 20]. The analysis in the present work used a
whole-brain approach, while accounting for the multiple tests
defined in the pre-registration [24].
MATERIALS AND METHODS
Participants
The current study is a pre-registered mega-analysis of structural MRI data
that had been collected at 28 research sites and repositories from Brazil,
Europe, and the USA [24]. As ENIGMA-GAD is an ongoing collaboration,
new research groups are encouraged to join. Some site-specific results
have been reported before, including from the National Institute of Mental
Health (NIMH) team leading the current project [16, 18, 25–29]. However,
no reports have examined results across these and additional samples
using a pre-registered plan. Twenty-five ENIGMA-GAD sites sent raw
individual participant MRI data. Additionally, raw structural MRI data were
downloaded from three publicly available imaging repositories to increase
sample size and thus, allow more stable estimates of eventual effects:
Adolescent Brain Cognitive Development Study (ABCD) [30, 31], Child Mind
Institute Healthy Brain Network (CMI-HBN) [32], and Duke Preschool
Anxiety Study [33]. All 25 research sites signed an individual data use
agreement with the NIMH that included regulations about data use,
subject identification, data transfer methods, data ownership, and
confidentiality and security practices [23]. Data use guidelines of the
repositories were followed. All adult participants and parents of child
participants provided written informed consent at their local research site,
and the individual research protocols were approved by local institutional
review boards and ethics committees.
Data were included if individuals were diagnosed with current or past
GAD2, not necessarily as the primary diagnosis. Exclusion criteria for
individuals with GAD were current or past autism spectrum disorders,
bipolar disorder, psychosis, or schizophrenia. These decisions regarding
inclusion and exclusion reflected past results from ENIGMA, where robust
differences in morphometry were found in studies of the excluded
conditions [1, 4]. Comparison subjects were excluded if they had any
current or past mental disorder. Diagnoses were based on standardized
interviews with a clinician at each research site (see Bas-Hoogendam et al.
(2020) for an overview).
We received data from 5523 participants before pre-registration [24]
(Table 1 shows the number of participants in each step of the analysis).
There were some small changes to this number after pre-registration and
before pre-processing of the data (see Supplementary Information for the
exact numbers and reasons per site for the differences). Table 2 shows the
reasons for excluding data. The main pre-registered analysis with random
slopes for all independent variables per site and random intercepts per
scanner included 1020 individuals with GAD (685 females, Mage= 23.65
years, SDage= 13.15) and 2999 healthy controls (1617 females, Mage=
14.76 years, SDage= 10.01), ranging from 5 to 90 years (Fig. 1). Table 3
shows descriptive statistics, Table 4 comorbid diagnoses for individuals
with GAD, and Table 5 medication status for participants included in this
main analysis. More sites and participants could be included in the
secondary analysis with fixed slopes for all independent variables and
random intercepts per scanner: 1112 individuals with GAD (753 females)
and 3282 healthy controls (1805 females), ranging from 5 to 90 years (M=
18.47, SD= 12.72). These additional participants were from sites that had
sample sizes that were too small to allow modeling random slopes (see
statistical analysis); these sites could only be included with fixed slopes.
Supplementary Table 1 shows the descriptive statistics, Supplementary
Table 2 the comorbid diagnoses for individuals with GAD, and
Supplementary Table 3 medication status for the participants who were
included in this secondary analysis. The three imaging repositories
consisted of data from multiple scanners: ABCD (29 scanners), CMI-HBN
(4 scanners), and Duke (2 scanners). In addition, two sites also contributed
data from multiple scanners: Brazilian High Risk Cohort Study (BHRCS;
2 scanners) and Section on Development and Affective Neuroscience
(SDAN; 4 scanners).
Non-imaging data
All research sites were asked to provide information with respect to several
variables of possible interest, such as demographic information (age, sex,
IQ, education in years), diagnoses, and information from a clinical interview
concerning anxiety (GAD, social anxiety disorder [SAD], panic disorder [PD],
agoraphobia [AG], specific phobia [SPH], any other anxiety disorder, age of
onset of anxiety disorders) and other disorders (MDD, obsessive-
compulsive disorder [OCD], post-traumatic stress disorder [PTSD], sub-
stance use dependence [SUD], other psychiatric disorders, age of onset of
other disorders), psychotropic medication use at the time of scan (selective
serotonin reuptake inhibitor [SSRI], serotonin and norepinephrine reuptake
inhibitor [SNRI], benzodiazepines, antipsychotic, other medication, and
duration of medication currently used), and several questionnaires
measuring continuous anxiety symptoms (see Supplementary Informa-
tion). Insufficient data were available for analyses with continuous anxiety
symptoms. Availability of these variables varied per research site. If the
information on medication was missing for some participants within a site,
a regressor for “Missing Medication” was added (this was the case for
A. Harrewijn et al.
2












































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































A. Harrewijn et al.
3











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































A. Harrewijn et al.
4
Translational Psychiatry          (2021) 11:502 
Baylor and CMI-HBN). If the information on medication was missing for all
participants within a site, medication was not included as an independent
variable in the analyses for that site.
Image processing
All raw structural MRI images that were received were organized according
to the Brain Imaging Data Structure (BIDS) specification and MRI Quality
Control (MRIQC) [34] was used for quality checking. All images were
subsequently processed with FreeSurfer version 6.0.0 [35] to compute
regional measures of cortical thickness, cortical surface area, and
subcortical volume. For participants with multiple images available, we
selected the image with the highest quality based on the Euler number
[36], which is calculated separately for left and right hemispheres. To
compare a single value across multiple images, we first selected the worst
(farthest from zero, lowest quality) Euler number per image. Then, we
selected the image with the best (closer to zero, highest quality) Euler
number. All data were visually inspected for gross over- or underestimation
of the white/pial surfaces (largely due to motion artifacts). We also
performed a semi-automated quality checking of the data by using the
ratio between the Euler characteristic and the number of vertices in the
surfaces before topology correction, defining site-specific thresholds using
a ROC curve constructed using the results of the visual inspection [23]. We
resampled the cortical measurements of thickness and area to an
icosahedron recursively subdivided four times (fsaverage4), which was
used as a common grid for interpolation [37]. Table 2 shows the number of
participants excluded based on visual and automatic quality checking.
Statistical analysis
We compared cortical thickness, cortical surface area, and subcortical
volume between individuals with GAD and healthy controls, and examined
interactions with age and sex. The dependent variables in the main
analysis were cortical thickness and surface area of the 68 regions of the
Desikan–Killiany parcellation [38], as well as subcortical volumes for
16 subcortical regions [35]. Two sets of independent variables were
considered, each in its own model. The first set consisted of GAD, sex, age,
age-squared, and their interactions, with covariates comprising IQ, years of
education, medication use at the time of the scan, each of the comorbid
disorders (SAD, PD, AG, SPH, MDD, OCD, PTSD, SUD), and scanner. The
second model was the same as the first, but further included global brain
measures (i.e., total surface area, mean cortical thickness, and total
intracranial volume) as nuisance variables. Both models in this main
analysis used random slopes (per site) and random intercepts (per
scanner); see Supplementary Table 4 for an overview of the analysis.
Variance groups, one per scanner, were used to accommodate the
possibility of different variances across scanners (heteroscedasticity;
smallest variance group had two observations). Together with permutation
testing, this eschews the need for explicit data harmonization. We tested
six contrasts per model: main effect of GAD (positive and negative), two-
way interaction between GAD and sex (positive and negative), two-way
interaction between GAD and age, and the three-way interaction between
GAD, age, and sex. The linear and quadratic effects of age were combined
using an F-test. All analyses were performed using the software
Permutation Analysis of Linear Models (PALM)3 with 500 permutations.
The p-values were computed after fitting a generalized Pareto distribution
to the tail of the permutation distribution [39] thus dispensing with the
need of performing a computationally prohibitive large number of
permutations. We repeated this main analysis with vertex-wise cortical
surface area and thickness as dependent variables (2562 vertices).
Independent variables, variance groups, contrasts, and the number of
permutations remained the same.
We used family-wise error rate (FWER) correction to address multiple
testing. Correction considered all tests within each modality (i.e., 68 cortical
regions each for cortical thickness and surface area, and 16 subcortical
volumes), all three sets of modalities, and all 12 contrasts. As the correction
considers all sets of modalities (or dependent variables) and all contrasts, it
is termed MC-FWER (family-wise error rate across modalities and contrasts)
[40]. Results at lower levels of correction for multiple testing (e.g., only
within a modality, or only across contrasts) are reported in the
Supplementary Information (Supplementary Figs. 1 and 2).
All sites provided information on GAD, age, and sex, but the inclusion of
the other independent variables varied across sites according to data
availability (see Supplementary Table 5 for an overview of the exact
independent variables included per site). Participants with missing values
in the independent variables (exact variables differed per site) were
excluded. Ultimately, the main analysis included 1020 individuals with GAD
and 2999 healthy controls. Because 192 participants had to be excluded
from the main analysis due to missing IQ and/or education in years, we
repeated the main analysis with these two variables removed for all sites;
the respective results for the regional and vertex-wise data are reported in
the Supplementary Information.
In addition, we ran a secondary analysis with the same dependent and
independent variables, but this time using fixed slopes across sites, while
keeping the random intercepts per scanner. This analysis allowed the
inclusion of more sites and participants, but it assumes that effects are the
same (fixed) across all sites. This secondary analysis included 1112
Fig. 1 Violin plots of the age distribution for all sites in the main analysis. ABCD Adolescent Brain Cognitive Development Study, BHRCS
Brazilian High Risk Cohort Study, CMI-HBN Child Mind Institute Healthy Brain Network, IOL Institute of Living, SDAN Section on Development
and Affective Neuroscience, SHIP Study of Health in Pomerania, UCSD University of California – San Diego, UPenn University of Pennsylvania,
WashU Washington University.
A. Harrewijn et al.
5





































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































A. Harrewijn et al.
6
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































A. Harrewijn et al.
7
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































A. Harrewijn et al.
8
Translational Psychiatry          (2021) 11:502 
individuals with GAD and 3282 healthy controls. Exploratory analyses
including the volume of gray matter within subcortical structures




This study compared regional and vertex-wise cortical thickness,
cortical surface area, and subcortical volume between individuals
with GAD (n= 1020) and healthy controls (n= 2999) while also
examining interactions between GAD, age, and sex. The analysis
modeled random slopes for all independent variables per site and
random intercepts per scanner. No effects of GAD, nor interactions
between GAD, age, or sex on the regional and vertex-wise cortical
surface area, cortical thickness, and subcortical volume were
significant (see Figs. 2, 3 and Supplementary Figs. 3, 4 for vertex-
wise effect sizes). The results remained non-significant when
analyses were performed (a) with only the basic independent
variables (GAD, age, sex, and their interactions) and (b) when
adding the interaction between GAD and medication. The results
for the main effects of medication and comorbid disorders and
the interaction between GAD and medication were also non-
significant.
Secondary analysis
The secondary analysis included more participants (1112 indivi-
duals with GAD and 3282 healthy controls) and implemented
approaches more similar to those in other reports from the
ENIGMA collaboration. These analyses included fixed slopes for all
independent variables and random intercepts per scanner. For the
regional data, a significant negative interaction was found
between GAD and sex in the volume of the right ventral
diencephalon (R2= 0.006, pMC-FWER= 0.0496 for the whole model
fit), in the model without global brain measures as nuisance
variables. Male individuals with GAD showed greater volume in
the right ventral diencephalon compared to male healthy controls,
whereas there was no difference between the groups for females
(Fig. 4). The same secondary analysis with fixed slopes for all
independent variables and random intercepts per scanner was
performed for vertex-wise cortical surface area and thickness data.
There were no significant effects of GAD, nor interactions between
GAD, age, or sex.
DISCUSSION
The current study compared regional and vertex-wise cortical
thickness, cortical surface area, and subcortical volume between
individuals with GAD and healthy controls. Data from 28 sites were
Fig. 2 Effect sizes from the main analysis for vertex-wise cortical surface area with the design that included global brain measures as
nuisance variables. None of these was statistically significant.
A. Harrewijn et al.
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combined in a pre-registered analysis that used random slopes
and random intercepts to model cross-site heterogeneity. The
main analysis showed no effect of GAD on indices of brain
structure, nor interactions among GAD, age, or sex. We also
conducted a secondary analysis with fixed slopes and random
intercepts. This secondary analysis included more sites and thus
more participants. This secondary analysis indicated that males
with GAD have greater volume, on average, in the right ventral
diencephalon compared to healthy males, whereas female
individuals with GAD and healthy females did not differ.
Regional and vertex-wise indices of brain structure did not differ
between individuals with GAD and healthy controls in the main
analysis after multiple comparison corrections. When we did not
fully correct for multiple testing, by ignoring the multiplicity of
contrasts, there was an interaction between GAD and sex in the
left lateral orbitofrontal cortex surface area (Supplementary
Results). Prior studies have shown mixed results on the effect of
GAD on cortical thickness and surface area [18–20], whereas some
studies using VBM have revealed altered gray matter volume in
the PFC, amygdala, and hippocampus [15–17]. Small sample sizes
and analytical and clinical heterogeneity may account for
differences across studies. Here, we leveraged a mega-analysis
to mitigate these challenges and found no effect of GAD when
accounting for comorbid disorders. The null finding in this study
might indicate that these indices of brain structure do not
differentiate individuals with GAD from healthy controls. In
contrast, ENIGMA studies on MDD have shown significant
differences between individuals with MDD and healthy compar-
isons in hippocampal volume and cortical thickness in bilateral
medial OFC, cingulate cortex, insula, and temporal lobes. This
could indicate that MDD is more related to structural brain
differences than GAD, but this should be confirmed in future
studies combining data. Future mega-analyses in GAD could focus
on other imaging modalities (e.g., resting-state fMRI, task-based
fMRI) or finer imaging phenotypes (e.g., subfields, shape analysis),
combine data across imaging and other data types, or use
structural covariance analysis or other higher-order constructs for
better group differentiation. Some of these analyses have already
been started within the ENIGMA-Anxiety Working Group [6, 41].
The secondary analysis with fixed slopes and random intercepts
indicated that male individuals with GAD had, on average, greater
volume in the right ventral diencephalon compared to male
healthy controls, whereas there was no difference between
groups for females. The effect size was relatively small, which
may explain why this effect arose only in the secondary analysis
with more participants and fewer variables in the model. The
ventral diencephalon includes the hypothalamus4, which plays an
important role in the neuroendocrine stress response [42].
Fig. 3 Effect sizes from the main analysis for vertex-wise cortical thickness with the design that included global brain measures as
nuisance variables. None of these was statistically significant.
A. Harrewijn et al.
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Previous studies of GAD found lower hypothalamic volumes [43],
and these volumes were negatively associated with anxiety
severity in healthy adults [44]. However, these findings focus on
the hypothalamus specifically rather than the broader ventral
diencephalon region [43], and these samples included mostly
females with GAD. Our finding could represent an example of the
“gender paradox” hypothesis. This hypothesis posits that across
psychiatric disorders, the less frequently affected sex is the one
that manifests more severe features of the disorder [45]. This
finding is also in line with studies showing differences in structural
connectivity in boys but not girls with anxiety disorders [46].
The age range in this sample was large. Some of the largest sites
(ABCD, BHRCS) contributed mainly data from young healthy
controls, even though the median onset of GAD is in adulthood.
We accounted for this by including age and interactions with age
in the analysis. Additionally, quadratic effects of age were added
because age effects might not be linear [47]. However,
nonlinearities that were not modeled could have influenced the
data. There might be differences between childhood-onset and
adult-onset GAD, but not enough data on the age of onset was
available to investigate this further. Hence, interpretation should
be in the light of the composition of the sample, which is not a
random draw from any specific population, and the data available
for analysis. Future mega-analyses could try to collect more
detailed clinical data to further investigate childhood-onset and
adult-onset GAD.
A few limitations should be noted. First, individuals with current
and lifetime GAD were grouped together in the analysis, which
could have increased heterogeneity in the GAD group. In addition,
the distinction between individuals between current and lifetime
GAD might be particularly difficult in the 9–10-year-old children
from the ABCD data set. Only 12.9% of the individuals had a
diagnosis of lifetime (and not current) GAD at the time of the scan
and the results of the main analysis did not change when only
individuals with current GAD were included. Second, methods for
collecting imaging and non-imaging data differed across research
sites. Even though we have accounted for this in the analysis by
including random intercepts and slopes per site, it is possible that
residual site-specific non-linear effects may still have been present
in the data. Third, the results of the secondary analysis with fixed
slopes and random intercepts are mostly influenced by the larger
samples, such as the ABCD data set (n= 1451). However, the main
analysis with random slopes and random intercepts is robust to
this type of bias. Fourth, variance groups were not taken into
account when estimating effect sizes, so the effect sizes could be
diminished. Fifth, data quality might be different between sites,
which could influence the results, despite the fact that we took
certain aspects of heterogeneity into account in the analyses.
To summarize, there was no effect of GAD on regional or vertex-
wise cortical thickness, cortical surface area, and subcortical
volume, nor interactions among GAD, age, or sex. This is in line
with inconsistent findings from prior studies and the clinical
heterogeneity of GAD. The secondary analysis showed an
interaction between GAD and sex in the ventral diencephalon.
Male individuals with GAD showed greater volume in the right
ventral diencephalon compared to male healthy controls, whereas
there was no detectable difference between female individuals
with GAD and healthy controls. Together, these findings show that
associations between indices of brain structure and GAD are small,
underscoring the subtlety of its effects and perhaps also the
clinical heterogeneity of GAD as a phenotype. Showing these null
results in a large mega-analysis is important to inform future
studies on GAD to focus on other neuroimaging modalities and/or
other phenotyping approaches that favor dimensionality.
Footnotes
1. A meta-analysis involves the computation of a statistic from
several cohorts, prior to merging the statistics into an overall
estimate of effect size for a variable of interest. A mega-
analysis involves a centralized analysis of individual-level
data across a range of cohorts, modeling the effect of each
cohort and using all the available data to estimate an overall
effect size.
2. We repeated the analyses with only individuals with current
GAD (n= 881; one participant from the ABCD data set had
to be excluded, because they were the only participant from
one scanner, resulting in a variance group of 1 observation).
Similar to the results from individuals with both current and
lifetime GAD, the main analysis showed no significant
effects of GAD, nor significant interactions between GAD,
age, or sex on the regional and vertex-wise cortical surface
area, cortical thickness, and subcortical volume. In addition,
the secondary analysis with 982 individuals with current
GAD also revealed an interaction between GAD and sex in
the volume of the right ventral diencephalon, R2= 0.007,
pMC-FWER= 0.038 (for the whole model fit). However, in
contrast to the analysis with individuals with both current
and lifetime GAD, the vertex-wise secondary analysis
Fig. 4 An interaction between generalized anxiety disorder (GAD) and sex in volume in the right ventral diencephalon was observed;
male individuals with GAD showed greater volume (mm3) compared to male healthy controls, whereas there was no difference between
the groups for females. Figure shows data after nuisance variables have been considered (residuals). Average volume of the right ventral
diencephalon across individuals with GAD and HC: 3988.6 mm3. Note: Error bars reflect standard error.
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revealed an interaction between GAD and age in cortical
surface area in one vertex in the superior frontal gyrus in the
model with global brain measures (−21.23, 30.13, 48.52;
coordinates from FreeSurfer’s FreeView).
3. https://fsl.fmrib.ox.ac.uk/fsl/fslwiki/PALM.
4. Other ventral diencephalon structures include the mammil-
lary bodies, subthalamic nuclei, substantia nigra, red
nucleus, lateral and medial geniculate nuclei. Some white
matter structures such as the zona incerta, crus cerebri,
lenticular fasciculus, and the medial lemniscus are also
included in this region, as well as segments of the
optic tract.
CODE AVAILABILITY
Code for data cleaning and analysis will be made available upon request.
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